Table 2.
Concomitant therapies at screening
| % | Normal renal function* | Mild RI* | Moderate RI* | |||
|---|---|---|---|---|---|---|
| Linagliptin 5 mg (n = 870) | Placebo (n = 342) | Linagliptin 5 mg (n = 620) | Placebo (n = 218) | Linagliptin 5 mg (n = 68) | Placebo (n = 25) | |
| Subjects with ≥1 specific drug | 66.7 | 70.5 | 81.0 | 80.7 | 88.2 | 88.0 |
| ASA | 30.5 | 34.2 | 37.6 | 38.1 | 29.4 | 48.0 |
| Antihypertensives | 51.1 | 52.6 | 69.5 | 70.2 | 82.4 | 84.0 |
| β-blockers | 14.9 | 16.4 | 23.9 | 26.1 | 30.9 | 20.0 |
| ACE inhibitors | 26.9 | 26.9 | 30.0 | 31.7 | 33.8 | 48.0 |
| Diuretics | 8.7 | 9.6 | 18.5 | 14.7 | 32.4 | 32.0 |
| ARBs | 10.5 | 10.8 | 16.6 | 13.3 | 19.1 | 16.0 |
| Calcium antagonists | 11.0 | 11.7 | 20.2 | 19.7 | 27.9 | 24.0 |
| Combinations | 5.9 | 7.3 | 12.9 | 12.4 | 17.6 | 24.0 |
| Lipid-lowering drugs | 34.5 | 38.3 | 43.7 | 41.7 | 51.5 | 40.0 |
| Niacin | 1.6 | 0.3 | 1.1 | 0.5 | 0 | 0 |
| Fibrates | 4.8 | 7.0 | 7.6 | 7.3 | 7.4 | 16.0 |
| Statins | 30.0 | 31.9 | 37.4 | 35.8 | 45.6 | 32.0 |
| Other | 2.3 | 2.6 | 2.6 | 0.5 | 1.5 | 4.0 |
| Glucose-lowering drugs | ||||||
| Treatment-naïve | 8.3 | 11.4 | 15.6 | 22.9 | 10.3 | 4.0 |
| Metformin only | 28.3 | 27.5 | 29.0 | 30.3 | 25.0 | 24.0 |
| SU only | 1.8 | 3.2 | 3.1 | 2.3 | 1.5 | 8.0 |
| Metformin + SU | 59.8 | 56.4 | 50.6 | 43.1 | 60.3 | 64.0 |
| Others† | 1.8 | 1.5 | 1.6 | 1.4 | 2.9 | 0 |
ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor blockers; ASA, acetyl salicylic acid; MDRD, modification of diet in renal disease; RI, renal impairment; SU, sulphonylurea.
Renal function according to MDRD formula: normal, ≥90 ml/min/1.73 m2; mild, 60–<90 ml/min/1.73 m2; moderate, 30–<60 ml/min/1.73 m2.
Including mono- and combination therapies.